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INTRODUCTION
Lung cancer is a major health problem worldwide. The incidence is 
increasing globally at a rate of 0.5% per year. The worldwide incidence is 
14% whereas it constitutes 6.8% of all cancers in India. It is the leading 
cancer of both sexes in three of the Urban Cancer Registries (Bhopal, 
Delhi and Mumbai) in India. 1
Unlike  many  other  malignancies,  whose  causes  are  largely 
unknown, the cause of lung cancer is tobacco smoking in as many as 90% 
of  patients.  Although  the  relationship  between  cigarette  smoking  and 
squamous cell carcinoma and small cell carcinoma has long been clear, 
the  relationship  between  smoking  and  adenocarcinoma,  large  cell 
carcinoma has been more ambiguous. While the older literature suggest 
that smoking is unrelated to adenocarcinoma more recent data indicates 
that all the major histopathological types are related to smoking.2
 Adenocarcinoma is the most frequent Non Small Cell Cancer in the 
United States. Patterns of  lung cancer in India varies from the western 
population. Squamous cell carcinoma is the commonest variety in india 
as compared to adenocarcinoma in the west. 
            The type and location of cancer influences the presentation  in  
clinical practice.  Central or endobronchial growth of the primary tumor 
may  cause  cough,  hemoptysis,  wheeze  and  stridor,  dyspnea,  and 
postobstructive  pneumonitis  .  Peripheral  growth  of  the  primary  tumor 
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may cause pain from pleural or chest wall involvement, cough, dyspnea 
on a restrictive basis, and symptoms of lung abscess resulting from tumor 
cavitation.
            Although there are a plenty of studies relating smoking to 
Bronchogenic Carcinoma, there is a paucity of studies relating smoking 
to histopathological type.  This study will focus on the various clinical, 
radiological presentations of Bronchogenic Carcinoma and its correlation 
to histopathological type.
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AIM OF THE STUDY
1.  To assess the relationship of histological type of Bronchogenic 
Carcinoma to smoking. 
2. To study the clinical presentations of Bronchogenic Carcinoma.
3.  To document the radiological appearances of Bronchogenic 
Carcinoma with histopathological correlation.
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MATERIALS AND METHODS
               Patients attending out patient department, Thoracic Medicine, 
Coimbatore Medical College Hospital, Coimbatore who were diagnosed 
to have Bronchogenic Carcinoma were selected.
Study Design:
             Single Centre, Analytical Study
Study Period:
             Study was conducted between January 2007 and August 2008 for 
a period of 18 months.
Sample Size:
              In the study period of 18 months among patients attending 
Thoracic Medicine Out patient Department 50 patients were selected.
Selection Criteria:
            All patients who had histological or cytological confirmation of 
lung  cancer  determined  through  bronchoscopy,  CT  scan  guided 
FNAC/trucut biopsy or open biopsy are selected.  Informed oral consent 
obtained from all patients. Detailed history, clinical Examination, Basic 
Biochemical Investigations were done in all patients.
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REVIEW OF LITERATURE
SCENARIO OF LUNG CANCER IN INDIA
 Lung  cancer  is  the  leading  cause  of  cancer  death  in  men  and 
women in both the United States and the world. More Americans die each 
year of lung cancer than of colon, breast, and prostate cancer combined. 
The overall 5-year survival of lung cancer is 15% or less and has only 
shown minimal improvement over the past 30 years. 
Lung cancer was initially thought to be infrequent in India. Lung 
cancer constituted 14.4% of all cancers. In a review of  9210 consecutive 
autopsies by Banker and Sirsat reported that lung cancer formed one per 
cent of all cancers in Tata Cancer Hospital. Viswanathan et al25 collected 
information from different  hospitals of the country and found that  the 
incidence of lung cancer in hospital population was 27.4 per million in 
1950  and  in  78.6  per  million  in  1959.  Lung  cancer  has  remained 
predominantly a  disease of  males with a male to-female ratio ranging 
from 5.76:1 to 6.67:1. Around 80% of lung cancer patients come from the 
rural areas7. The demographic pattern of lung cancer in India is similar to 
that observed in Western countries 40 years ago. Forty per cent of patients 
of lung cancer are less than 50 years of age and 11% are less than 40 
years.7
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SMOKING AND LUNG CANCER
The vast majority (85–90%) of cases of lung cancer are attributable 
to  smoking,  and intensive research efforts  have identified hundreds of 
carcinogens contained in both mainstream smoke (smoke directly inhaled 
by  the  smoker)  and  sidestream smoke  (smoke  released  from burning 
tobacco between puffs plus smoke exhaled by the smoker). Although risk 
for lung cancer decreases significantly after smoking cessation, overall 
disease risk reduction takes years and an individual's risk never returns to 
that  of  a  never  smoker  (never  smoker  is  defined  as  fewer  than  100 
cigarettes  in  an  individual's  lifetime).  Historically,  20  pack-years  of 
tobacco exposure or more has been considered to contain the highest risk 
populations. Due to the large number of former smokers, new cases of 
lung cancer in the United States are diagnosed more commonly in former 
smokers than current smokers7.  Smoking of  bidi  and  hooka  as well as 
cigarettes had similar Odds ratios for cumulative consumption. The risk 
increased with both the duration and quantity of all smoking products. 
Environmental tobacco smoke is a known lung carcinogen. Another study 
by Rapiti  et al  has shown that environmental tobacco smoke exposure 
during childhood is strongly associated with the risk of later development 
of lung cancer.
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 Other environmental factors can contribute to the development of 
lung cancer. Of particular note, many of these exposures, when coupled 
with smoking, lead to exponential increases in the risk of developing lung 
cancer.  For  example,  smokers  with  asbestos  exposure  have  a  50–100 
times increased risk of developing lung cancer. 
ENVIRONMENTAL RISK FACTORS FOR DEVELOPING LUNG 
CANCER
Proven  
Passive/environmental tobacco smoke 
Radon gas 
Asbestos 
Metals (chromium, arsenic, iron oxide) 
Industrial (bischloromethyl ether) 
Polycyclic aromatic hydrocarbons 
Suspected  
  Air pollution 
  Vinyl chloride 
  Silica 
  History of tuberculosis
Genetics and lung cancer:
Cytogenetic studies have identified many chromosomal changes in 
lung cancer. These mutations include activation of the dominant cellular 
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protooncogenes  of  the  ras  and  myc  family  and  inactivation  of  the 
recessive or tumour suppressor genes. Small cell lung cancer is associated 
with oncogenes, like c-myc, L-myc, N-myc, c-raf and tumour suppressor 
genes, like p53 and Rb. Nonsmall cell lung cancer is associated with K-
ras,N-ras, H-ras, c-myc, c-raf and tumour suppressor genes like p16 and 
Rb genes. FHIT is a tumour-suppressor gene and is frequently altered in 
lung  cancer.  Apoptosis  or  programmed  cell  death  is  altered  in  lung 
cancers  due  to  changes  in  the  anti-(BCL-3,  Belxl)  and  proapoptotic 
members (Bax, Bad).
Diet And Lung Cancer:
There  is  some  evidence  that  certain  dietary  factors  may  be 
protective for lung cancer, and others may increase the risk. There are 
conflicting  reports  about  the  role  of  betacarotene  and  lung  cancer, 
although most reports suggest a protective effect.Sankaranarayanan found 
that  green  vegetables  and  bananas  have  a  protective  effect  on  the 
development  of  lung  cancer.  Pumpkins  and  onions  had  the  most 
consistent protective effect. On the other hand, animal food products and 
diary  products  have  a  predisposing  effect  onlung  cancer.  Dietary 
cholesterol and animal fat increases the risk of lung cancer. 
PATHOGENESIS:
 Cancer  develops  in  a  multistep  fashion  in  which  cells  become 
malignant  by  multiple  genetic  alterations  affecting  cellular  growth, 
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differentiation,  and  survival.  This  can  include  the  mutation  of  tumor 
suppressor  genes  (for  example  p53),  the  activation  of  oncogenes  (for 
example,  myc, jun, and  fos), and the transformation of apoptotic genes. 
The overwhelming majority of cases of lung cancer are due to cigarette 
smoking. It is estimated that of cases of lung cancer, 90% in men and 
80% in women are smoking related. Smoke contains hundreds of known 
carcinogens,  including  free  radical  oxidants  and  nonradical  oxidants, 
which can damage DNA, proteins, and lipids. The chronic inflammation 
accompanying repeated smoke exposure also leads to genetic alterations 
in bronchial cells and contributes to development of lung cancer. 
PATHOLOGICAL TYPES:
Small cell carcinoma:
This is a highly malignant tumour, with lymphocyte looking cells 
(twice the size of lymphocytes) – accounts for about 30% of lung cancer 
cases.  They  have  little  cytoplasm (i.e.:  histologically  basophilic).  The 
cells  grown  in  clusters.  Electron  microscopic  studies  show  dense 
neurosecretory granules in some of these cells,  and these granules are 
similar to those found in the neuroendocrine cells lining the bronchial 
epithelium. Also some cells exhibit presence of neuroendocrine markers 
such as: neuron-specific  enolase  and  parathormone like  active products. 
This suggests that these tumours have a origin from neuroendocrine cells 
lining  the  bronchial  epithelium.  Small  cell  carcinomas  have  strong 
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relationship to smoking, only 1% of non-smokers get it. They are usually 
located centrally in the hilar region. They metastasize rapidly, so surgical 
repair is not possible –  chemotherapy is best.  This sort of a tumour is 
commonly associated with a paraneoplastic syndrome (i.e.: especially if it 
produces ACTH & ADH).
Squamous Cell Carcinoma:
 This accounts for about 45% of lung cancer cases. It is strongly 
correlated to a  smoking history. It usually arises in the larger bronchi, 
more  proximally.  It  is  recognised  by  presence  of  individual  cell 
keratinisation  (keratin  production  causes  cell  death)  and  intercellular 
bridges.  This  type  of  cancer  is  commonly  associated  with:  Pancoast 
tumour (i.e.: apical lung tumours in the superior pulmonary sulcus that 
tend  to  invade  the  neural  structures  around  the  trachea,  cervical 
sympathetic plexus), hypercalcaemia. SCC is  least likely to metastatize, 
at autopsy 50% of cases are confined to the thorax. This type of cancer 
may respond well to surgery. 
Adenocarcinoma: 
This  accounts  for  about  20% of  lung cancer  cases.  This  is  still 
associated with smoking, but is the most  common type to occur in non-
smokers  &  women.  Histological  classification  includes  two  forms:  1) 
bronchial-derived adenocarcinoma (i.e.: derived from bronchial mucosa), 
2) bronchioloalveolar carcinoma (i.e.: derived from terminal bronchioles 
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–  specialised  cells  located  here).  Adenocarcinoma  lesions  are  located 
more  peripherally,  are  smaller,  and  vary  histologically  (glandular 
appearance   papillary lesions   solid mass).  80%  of these tumours 
contain mucin producing glands. 
Large Cell Carcinoma 
This type of tumours probably represent SSC / adenocarcinoma, 
but because their cells are so undifferentiated – that they can no longer be 
recognised in  the above category.  Some of these tumour cells  contain 
intracellular mucin, some cells  are multinuclear  (giant cell  carcinoma), 
some have cleared cells (clear cell carcinoma), some have spindle shaped 
cells (spindle cell carcinoma).                    
CLINICAL PRESENTATION 
The frequency of the common presenting symptoms of bronchial 
carcinoma
Symptom                     Frequency (%)
Cough 41
Chest pain 22
Cough and pain 15
 Hemoptysis 7
Chest infection < 5
Malaise < 5
Weight loss < 5
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Shortness of breath < 5
Hoarseness < 5
Symptoms due to local invasion:
The tumour may directly involve the pleura and ribs. Carcinoma in the 
apex of the lung can erode the ribs and involve the lower part  of the 
brachial plexus (C8, T1 and T2), causing severe pain in the shoulder and 
down the inner surface of the arm (Pancoast's tumour). The sympathetic 
ganglion  can  also  be  involved,  producing  Horner's  syndrome.  Hilar 
tumours  may  involve  the  recurrent  laryngeal  nerve,  causing  unilateral 
vocal  cord  paresis  with  hoarseness  and  a  bovine  cough.  Bronchial 
carcinoma can also directly invade the phrenic nerve, causing paralysis of 
the ipsilateral hemidiaphragm. It can involve the oesophagus, producing 
progressive  dysphagia,  and  the  pericardium,  producing  pericardial 
effusion and malignant dysrhythmias. 
Superior  vena caval  obstruction causes early  morning headache, 
facial congestion and oedema involving the upper limbs; the jugular veins 
are  distended,  as  are  the  veins  on  the  chest  that  form  a  collateral 
circulation with veins arising from the abdomen.
 Metastatic complications:
 Bony  metastases  are  common,  giving  rise  to  severe  pain  and 
pathological  fractures.  There  is  frequent  involvement  of  the  liver. 
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Secondary  deposits  in  the  brain  present  as  a  change  in  personality, 
epilepsy or as a focal neurological lesion. Spinal cord compression is not 
uncommon  and  requires  urgent  treatment.  Secondary  deposits  in  the 
adrenal  gland  are  a  very  frequent  post-mortem  finding  but  are  often 
asymptomatic.
Non-metastatic extrapulmonary manifestations:
 Cachexia (anorexia, weight loss, weakness)
 Fever
 Hypertension
Endocrinological 
 Hypercalcemia
 Hyponatremia
 Cushing's syndrome
 Gynecomastia
 Acromegaly
 Hypoglycemia
Neurological 
 Lambert–Eaton myasthenic syndrome
 Peripheral neuropathy
 Cerebellar degeneration
 Limbic encephalitis
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 Encephalomyelitis
Musculoskeletal 
 Clubbing
 Hypertrophic pulmonary osteoarthropathy
 Dermatomyositis
 Polymyositis
Hematological 
 Anemia
 Autoimmune hemolytic anemia
 Leukocytosis/thrombocytosis
 Vasculitis
 Noninfectious thrombotic endocarditis
 Idiopathic thrombocytopenic purpura
Hypertrophic  pulmonary  osteoarthropathy (HPOA)  occurs  in 
approximately 3% of all bronchial carcinomas, particularly squamous-cell 
carcinomas and adenocarcinomas. Symptoms include joint stiffness and 
severe  pain  in  the  wrists  and  ankles,  sometimes  associated  with 
gynaecomastia. X-rays show a characteristic proliferative periostitis at the 
distal ends of long bones, which have an onion-skin appearance. HPOA is 
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invariably associated with clubbing of the fingers. It  may regress after 
resection of the lung tumour or as a result of vagotomy at thoracotomy.
STAGING OF BRONCHOGENIC CARCINOMA
Stage T N M Description 
0 Tis   Carcinoma in situ
IA T1 N0 M0 Limited local disease without nodal or 
distant metastases
IB T2 N0 M0  
IIA T1 N1 M0 Limited local disease with ipsilateral 
hilar  or  peribronchial  nodal 
involvement  but  not  distant 
metastases or
IIB T2 N1 M0
 T3 N0 M0 Locally  invasive  disease  without 
nodal or distant metastases
IIIA T3 N1 M0 Locally  invasive  disease  with 
ipsilateral  or  peribronchial  nodal 
involvement  but  not  distant 
metastases or
 T1–3 N2 M0 Limited  or  locally  invasive  disease 
with  ipsilateral  mediastinal  or 
subcarinal nodal involvement but not 
distant metastases
IIIB Any 
T
N3 M0 Any  primary  with  contralateral 
mediastinal  or  hilar  nodes,  or 
ipsilateral  scalene  or  supraclavicular 
nodes or
 T4 Any N M0 Unresectable local invasion with any 
degree of  adenopathy but  no distant 
metatases; malignant pleural effusion
IV Any 
T
Any N M1 Distant metastases
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Primary Tumor (T) 
TX Primary tumor cannot be assessed; or tumor proved by the presence 
of malignant cells in sputum or bronchial washings but not visualized by 
imaging or bronchoscopy.
T0 No evidence of primary tumor.
Tis Carcinoma in situ.
T1 A tumor  3 cm in greatest dimension, surrounded by lung or 
visceral pleura, and without evidence of invasion proximal to a lobar 
bronchus at bronchoscopy.
T2 A tumor > 3.0 cm in greatest dimension, or a tumor of any size that 
either involves a main bronchus (but is  2 cm distal to the carina), invades 
the  visceral  pleura,  or  has  associated  atelectasis  or  obstructive 
pneumonitis extending to the hilar region. Any associated atelectasis or 
obstructive pneumonitis must involve less than an entire lung. 
T3 A tumor  of  any  size  with  direct  extension  into  the  chest  wall 
(including superior sulcus tumors), the diaphragm, the mediastinal pleura, 
or the parietal pericardium; or a tumor in the main bronchus < 2 cm distal 
to  the carina without  involving the carina;  or  associated  atelectasis  or 
obstructive pneumonitis of the entire lung.
T4 A tumor of any size with invasion of the mediastinum, heart, great 
vessels, trachea, esophagus, vertebral body, or carina; or with a malignant 
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pleural or pericardial effusion; or with satellite tumor nodules within the 
ipsilateral lobe of the lung containing the primary tumor.
Regional Lymph Nodes (N) 
NX Regional lymph nodes cannot be assessed.
N0 No demonstrable metastasis to regional lymph nodes. 
N1 Metastasis to lymph nodes in the peribronchial or the ipsilateral 
hilar region, or both, including direct extension.
N2 Metastasis to ipsilateral mediastinal lymph nodes and/or subcarinal 
lymph nodes.
N3 Metastasis to contralateral mediastinal lymph nodes, contralateral 
hilar lymph nodes, ipsilateral or contralateral scalene or supraclavicular 
lymph nodes.
Distant Metastases (M) 
MX Presence of distant metastasis cannot be assessed.
M0 No (known) distant metastasis.
M1 Distant metastasis present.
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DIAGNOSIS OF BRONCHOGENIC CARCINOMA
 The diagnosis of lung cancer rests on examination of a tissue or 
cytology specimen. Sputum cytology is highly specific but insensitive; 
the  yield  is  highest  when  there  are  lesions  in  the  central  airways. 
Thoracentesis (sensitivity 50–65%) can be used to establish a diagnosis 
of lung cancer in patients with malignant pleural effusions. If cytologic 
examination  of  an  adequate  sample  (50–100  mL)  of  pleural  fluid  is 
nondiagnostic, the procedure should be repeated once. If results remain 
negative, thoracoscopy is preferred to blind pleural biopsy. Fine-needle 
aspiration (FNA) of palpable supraclavicular or cervical lymph nodes is 
frequently  diagnostic.  Serum tumor  markers  are  neither  sensitive  nor 
specific enough to aid in diagnosis.   
     Fiberoptic bronchoscopy allows visualization of the major airways, 
cytology  brushing  of  visible  lesions  or  lavage  of  lung  segments  with 
cytologic  evaluation  of  specimens,  direct  biopsy  of  endobronchial 
abnormalities, blind transbronchial biopsy of the pulmonary parenchyma 
or  peripheral  nodules,  and  FNA biopsy  of  mediastinal  lymph  nodes. 
Diagnostic yield varies widely (10–90%) depending on the size of the 
lesion  and  its  location.  Recent  advances  include  fluorescence 
bronchoscopy, which improves the ability to identify early endobronchial 
lesions;  and  endoscopic  ultrasound,  which  permits  more  accurate 
direction  of  FNA.  Transthoracic  needle  aspiration  (TTNA)  has  a 
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sensitivity  between  50%  and  97%.  Mediastinoscopy,  video-assisted 
thoracoscopic surgery (VATS), and thoracotomy are necessary in cases 
where less invasive techniques fail to yield a diagnosis.
Part A: Recommended tests for all patients  
 Complete blood count 
 Electrolytes, calcium, alkaline phosphatase, albumin, AST, ALT, 
total bilirubin, creatinine 
 Chest radiograph 
 CT of chest through the adrenal glands.
 Pathologic confirmation of malignancy 
Part B: Recommended tests for selected but not all patients:
MANAGEMENT OF LUNG CANCER
Surgery:
Surgery,  radiotherapy and  chemotherapy  are  the  various  options 
available  for  the  management  of  lung  cancer.  In  the  early  stages  of 
NSCLC (Stage I to IIIA), surgery if feasible is the treatment of choice. 
The  five-year  survival  rate  after  surgery  are  as  follows:  Stage  I:  60-
70%,State IA: (T1N0), 80%, Stage II: 35-40%, Stage IIIA (N2): 10-15%. 
As  most  cases  of  lung  cancer  present  in  an  advanced  and inoperable 
stage, and radiotherapy is only a local form of therapy, chemotherapy has 
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an important role in the management of lung cancer. Several regimens of 
chemotherapeutic agents have been studied in lung cancer. In a recent 
meta-analysis  of  randomized  trials  that  compared  chemotherapy  with 
good supportive care, chemotherapy showed a modest benefit. There is an 
improvement in the quality of life, prolongation of median survival by 
1.5-3 months, increased survival at one year by 10% and a reduction in 
the risk of death by 27 percent. 
Chemotheraphy:
Chemotherapy is indicated for stage III B, stage IV non small cell 
carcinoma and all small cell carcinoma patients. Newer chemotherapeutic 
agents  that  have  increased  one-year  survival  up  to  40%  and  median 
survival of about 8-9 months are being increasingly used now a days . 
These  include  Gemeitabine,  Docetaxel,  paclitaxel,  Vinorelbine, 
Topotecan,  Irinotecan,  and  Newer  Platinum  agents  (carboplatin, 
Oxaloplatin,  etc).  Combinations  of  a  platinum  agent  with  a  new 
generation cytotoxic agent have become the standard of care for first-line 
chemotherapy of advanced non-small cell lung cancer. In the presence of 
contraindications  for  platinumbased  chemotherapy,  platinum-free 
chemotherapy  might  be  a  reasonable  option.  There  is  not  enough 
evidence to support the use of triple-drug chemotherapy. Administration 
of single-agent gemcitabine or vinorelbine can be considered in patients 
with  poor  performance  status  and  in  elderly  patients.  In  case  of 
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nonprogression and lack of severe toxicity, the administration of four to 
six cycles of chemotherapy is recommended. There is no evidence that 
prolongation  of  treatment  has  an  impact  upon  survival.  Second  line 
chemotherapy  using  docetaxel  should  be  considered  for 
chemotherapeutically pre-treated patients with good performance status 
in order to relieve symptoms, prolong survival and improve quality of 
life.  Studies  from  India  have  shown  that  without  chemotherpay  the 
median  survival  of  unresectable  NSCLC is  five  weeks,  with  a  single 
agent it is 7.5 weeks, with less effective chemotherapy it is 9.5 weeks and 
with modern chemotherapy it is 23 weeks to more than 40 weeks. The 
problems with chemotherapy in India include a large number of dropouts, 
because of the costs and the side effects.
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DATA ANALYSIS
TABLE 1
TABLE SHOWING SEX INCIDENCE
Table 1 shows that out of 45 patients  41(91%) were male and 4(9%) 
were female. The male to female ratio is 14:1.
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TABLE 2
AGE INCIDENCE OF BRONCHOGENIC CARCINOMA
Age Male Female
41 to 50 4 0
51 to 60 23 3
61 to 70 18 0
From the above table it is found that 26 patients were within the 
age group 51 to 60 years which constitutes 57% of the patients studied. 
Only 4 patients were below 50 years and the rest 41 patients (91%)  were 
above 50 years.
The mean age of incidence as per study is 59 years both in males 
and females.
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TABLE 3
PREVALENCE OF SMOKING IN MALES AND FEMALES
Male Female
Smokers 40 1
Non Smokers 1 3
Among 45 patients studied 41(91%)  were smokers and 4 were non 
smokers. Among 4 females studied 3 were non smokers and one had the 
habit of tobacco chewing.
TABLE 4
TABLE SHOWING DIFFERENT SMOKING PATTERNS
Among 42 patients who are smokers, 34 patients smoked bidi, 17 
patients cigarette, 10 patients both bidi and cigarette and one patient had 
the habit of tobacco chewing.
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TABLE 5
CORRELATION OF PACK YEARS AND BRONCHOGENIC 
CARCINOMA
Out  of  41  patients  who  are  smokers,  15  patients(36.5%)  had 
smoking pack years less than 40 and 26 patients(53.4%) had pack years 
greater  than 40.  The maximum number  of   patients  nearly  56%  had 
smoking pack year between 41 to 80.
32
TABLE 6
CORRELATION OF TYPE OF BRONCHOGENIC CARCINOMA 
WITH SMOKING
Pathological type of 
tumor Smokers Non smokers
Squamous cell 
carcinoma 26 3
Adenocarcinoma 11 1
Small cell carcinoma 4 0
            Out of 29 patients who had squamous cell carcinoma, 26 were 
smokers and 3 were non smokers. Among 12 patients who had  adeno 
carcinoma 11 were smokers and one patient was a non smoker. The 4 
patients found to have small cell carcinoma were smokers.
                  Among the 4 patients who were non smokers, 2 had 
adenocarcinoma and 2 had squamous cell carcinoma.
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TABLE 7
TABLE SHOWING COMMON SYMPTOMS IN 
BRONCHOGENIC CARCINOMA
Symptoms No of patients Percent
Cough 44 97
Dyspnoea 26 57
Hemoptysis 23 51
Chest pain 20 44
Hiccough 3 6
Hoarseness of voice 2 4
Dysphagia 2 4
Brachial neuralgia 1 2
Out of 45 patients studied almost every patient had (97 %) cough 
as the predominant symptom. Dyspnoea is the next common presenting 
symptom which is present in 26 patients(57%).  Hemoptysis is present in 
51  % of  patients  and  chest  pain  in  44  % of  patients.  The  remaining 
symptoms  found  in  small  no  of  patients  are  hoarseness  of  voice, 
dysphagia, hiccough and brachial neuralgia.
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TABLE 8
RELATIONSHIP BETWEEN SVC OBSTRUCTION AND 
PATHOLOGICAL TYPE
SVC 
obstruction
Squamous cell 
carcinoma
Adeno 
carcinoma
Small cell 
carcinoma
Present 2 12 0
Absent 27 0 4
Superior venacava obstruction is seen in 2 patients in our study and 
they both were found to have squamous cell carcinoma.
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TABLE 9
RELATIONSHIP OF CLUBBING WITH PATHOLOGICAL TYPE 
OF BRONCHOGENIC CARCINOMA
Clubbing Present Absent
Squamous cell 
carcinoma
17 12
Adeno carcinoma 2 10
Small cell 
carcinoma
0 4
Clubbing  was  present  in  19  patients  in  the  study.  Out  of  19 
patients,  17  patients(89%)  had  squamous  cell  carcinoma  and  the 
remaining 2 had adenocarcinoma.
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TABLE 10
INCIDENCE OF PATHOLOGICAL TYPES OF BRONCHOGENIC 
CARCINOMA
Pathological type No of patients Percent
Squamous cell 
carcinoma
29 64
Adenocarcinoma 12 26
Small cell carcinoma 4 8
Among  45  patients  with  bronchogenic  carcinoma  29  patients 
(64%)  had  squamous  cell  carcinoma,  12  patients  (26%)  had 
adenocarcinoma and 4 patients(8%) had small cell carcinoma.
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TABLE 11
RELATIONSHIP BETWEEN PATHOLOGICAL TYPE AND SEX 
OF THE PATIENT
Pathological type Male Female
Squamous cell carcinoma 27 2
Adenocarcinoma 10 2
Small cell carcinoma 4 0
Out of 29 patients with squamous cell carcinoma 27 patients were 
males  and  2  patients  were  females.  Out  of  12  patients  with 
adenocarcinoma 10 were males and 2 were females. Among 4 patients 
with small cell carcinoma 4 were males.
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TABLE 12
CORRELATION BETWEEN PATHOLOGICAL TYPE AND 
LOCATION OF TUMOR
Pathological type Central Peripheral Total
Squamous cell 
carcinoma
20(69%) 9(31%) 29
Adeno carcinoma 3(25%) 9(75%) 12
Small cell 
carcinoma
4 0 4
Total 27(60%) 18(40%) 45
Among  29  patients  with  squamous  cell  carcinoma  20 
patients(69%)  had  centrally  located  tumor  and  9  patients(31%)  had 
peripheral  tumor.  Among  12  patients  with  adenocarcinoma,  9 
patients(75%)  had  peripheral  tumor  and  3  patients(25%)  had  central 
tumor.  Among  4  patients  with  small  cell  carcinoma  4  had  centrally 
located tumor.
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TABLE 13
RELATIONSHIP BETWEEN THE RADIOLOGICAL PATTERN 
AND PATHOLOGICAL TYPE OF BRONCHOGENIC 
CARCINOMA
Radiological 
pattern
Squamous cell 
carcinoma
Adeno 
carcinoma
Small cell 
carcinoma
Mass lesion 23 5 3
Pleural effusion 3 3 1
Obstructive 
pneumonia 2 3 0
Mediastinal 
invasion 1 2 1
Rib erosion 5 5 1
Calcification 1 1 0
Cavitation 1 0 0
Out of 45 patients, 31 patients(69%) presented as mass lesion in 
the lung, 7 patients(15%) presented as pleural effusion, 5 patients(11%) 
presented as obstructive pneumonia. 
Among  29  patients  with  squamous  cell  carcinoma  23  patients 
(79%)  presented  as  mass  lesion,  followed  by  pleural  effusion  and 
obstructive  pneumonia.  Among  12  patients  with  adeno  carcinoma  5 
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patients(41%)  presented  as  mass  lesion,  3  patients(25%)  as  pleural 
effusion and 3(25%) patients as obstructive pneumonia. In the small cell 
carcinoma  three  patients  presented  as  mass  lesion  and  one  patient  as 
obstructive pneumonia.
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TABLE 14
CORRELATION BETWEEN RADIOLOGICAL PATTERN AND 
LOCATION OF LESION
Radiological pattern Central Peripheral
Mass lesion 22 9
Pleural effusion 2 5
Obstructive 
pneumonia 2 3
Mediastinal invasion 2 2
Rib erosion 4 7
Calcification 1 1
Cavitation 0 1
Among  45  patients  with  bronchogenic  carcinoma  27  patients 
(60%) presented as a mass lesion, 7 patients (15%) presented as pleural 
effusion and 5 patients (11%) presented as obstructive pneumonia.
Among the central tumors, 22 patients (81%) presented as mass lesion, 2 
patients(7%)  as  pleural  effusion  and  2  patients(7%)  as  obstructive 
pneumonia.
Among  peripheral  tumors  9  patients(50%)  presented  as  mass 
lesion,  5  patients(27.7%)  presented  as  pleural  effusion  and  3 
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patients(16.6%) presented as obstructive pneumonia.
Among 45 patients with bronchogenic carcinoma, 11 patients had 
rib  invasion,  4  patients  had  mediastinal  invasion,  2  patients  had 
calcification and one patient had cavitation.
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TABLE 15
TABLE SHOWING RELATIONSHIP BETWEEN 
PATHOLOGICAL TYPES AND METASTASIS
Metastasis
Squamous 
cell 
carcinoma
Adeno 
carcinoma
Small cell 
carcinoma
Lymph node 8 1 0
Liver 4 1 1
Skeletal 0 1 0
Brain 4 2 1
Adrenal 1 1 0
Spleen 1 0 0
Intra pulmonary 1 0 0
9(20%) patients out of 45 patients had supraclavicular lymphnode 
metastasis.  Six (13%) patients  out  of  45 patients  had liver  metastasis. 
Seven  patients(15%)   out  of  45  had  brain  metastasis.  2  patients  had 
adrenal, one patient had spleen and one had intrapulmonary secondaries.
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TABLE 16
RELATIONSHIP BETWEEN THE PATHOLOGICAL TYPE AND 
LOBE INVOLVEMENT
Lobe Squamous cell carcinoma
Adeno 
carcinoma
Small cell 
carcinoma Total
Right upper 
lobe 8 6 1 15
Right middle 
lobe 3 0 0 3
Right lower 
lobe 7 4 1 12
Left upper lobe 9 2 1 12
Left lower lobe 2 0 1 3
Out of 45 patients, 15 patients (33%) had the lesion in right upper 
lobe,  3  patients  (6%)  had  the  lesion  in  right  middle  lobe,  12 
patients(26.6%) had the lesion in right lower lobe. 
Among 45 patients,12 patients (26.6%) had lesion in the left upper 
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lobe and 3 patients (6%) had lesion in the left lower lobe. 
Out of 45 patients, 30 patients(66.6%) had lesion in the right side 
and the remaining 15(33%) patients had the lesion in the left lobe.  
Out of 45 patients, 30 patients had the lesion located in the upper 
lobe(including middle lobe) and 15 patients in the lower lobe.
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DISCUSSION
SEX  INCIDENCE
The male to female ratio in our study is 14: 1. 
In a study conducted in northern india in Chandigarh in 20051, the 
overall male to female ratio is 5.2 : 1, which is much low when compared 
to our study. In a study conducted in Pakistan in the year 20022 the male 
to female ratio is 6: 1. In western countries the sex ratio is in the range of 
3to 4: 1. 
The recent increase in incidence among women in the West, which 
has been associated with a great increase in their smoking, may now give 
rise to the fall in sex ratio which Ochsner and De Bakey anticipated44. 
The  low incidence  in  south  Indians  is  attributed  to  less  incidence  of 
smoking in women.
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AGE INCIDENCE OF BRONCHOGENIC CARCINOMA
The average age incidence in our study is 59 years, which is similar 
to  the  study  conducted  in  Chandigarh  in  20051.  In  the  study  done  in 
western Nepal17 in 2001 the median age of the male and female patients 
was 67 and 66 years respectively. Increased smoking, urbanisation, and 
the  introduction  of  new  industries  has  probably  led  to  a  rise  in  the 
incidence of bronchogenic carcinoma in India at an earlier age.
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PREVALENCE OF SMOKING IN MALES AND FEMALES
In our study among 41 males 40 were smokers. Among 4 females 
one was a smoker.  Smoking as a major risk factor  in development of 
bronchogenic carcinoma among males is statistically significant with p 
value <0.05.
Our  result  correlates  with  the  study  in  northern  india  In 
Chandigarh1. Our study also correlates with the study by CM shetty in 
Karnataka3 where all non smokers were females. The less prevalence of 
smoking  in  females  also  attributes  to  less  incidence  of  bronchogenic 
carcinoma  among  females.  Smoking  is  a  major  risk  factor  for 
development of bronchogenic carcinoma in males. Other risk factors like 
occupational  exposure to asbestos,  arsenic, nickel,  radiation, hereditary 
predisposition and passive smoking should be thought of in non smokers.
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PREVALENCE OF DIFFERENT SMOKING PATTERNS
The most common pattern of smoking in our study is bidi (55%). 
Twenty seven percent had the habit of smoking cigarette. 16% had the 
habit of smoking both bidi and cigarette.  One female had the habit of 
smoking tobacco.
In the study conducted in northern india1, bidi smoking is the major 
pattern in Chandigarh patients affected by bronchogenic carcinoma. Bidi 
and cigarette scored the second place followed by cigarette alone as in 
our study.
In India the smoking of manufactured cigarettes is less common 
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than in Western countries. Not only do bidis contain less tobacco than the 
common types of Indian cigarettes but the tobacco is dried naturally and 
in this respect resembles cigar and pipe tobacco. Bidi smokers generally 
inhale  deeply  and  Jindal  and  Malik40 showed  that  as  great  a  rise  in 
carboxyhaemoglobin  concentration  may  occur  after  smoking a  bidi  as 
after  a  cigarette.   Possibly  therefore  the  lower  risk  of  carcinoma 
associated with pipes and cigars is due not to their containing naturally 
cured tobacco (as opposed to the flue-cured tobacco of cigarettes)  but 
rather to the fact  that  pipe and cigar smokers generally do not inhale. 
Hence bidi smokers generally inhale deeply and have a greater risk of 
developing  bronchogenic  carcinoma  when  compared  to  cigarette 
smokers.
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RELATIONSHIP BETWEEN PATHOLOGICAL TYPES AND 
SMOKING
In  our  study  among  29  patients  with  squamous  cell  carcinoma 
26(89%)  were  smokers   and  3(11%)  were  non  smokers.  Among  12 
patients with adenocarcinoma 11 were smokers. Among 4 patients with 
small cell carcinoma all were smokers. The role of tobacco smoke in the 
development of lung cancer is well known for squamous and small cell 
types,  somewhat less so for  adenocarcinoma. In a study conducted by 
Morabia A, Wynder EL45, in USA smoking was associated with each lung 
cancer cell  type, and differences in smoking habits by cell  types were 
small. 
Similar to the above said study, in our study all pathological types 
of bronchogenic carcinoma were associated with smoking.
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CORRELATION OF PACK YEARS AND BRONCHOGENIC 
CARCINOMA
Out of 45 patients 26 patients (63%) had pack years of smoking 
greater than 40 and 15 patients (37%) had pack years less than 40. 
In a study conducted by Stefan Diederich, M.D et al22 in germany, 
they did ct  scan thorax among 700 assymptomatic  smokers with pack 
years > 40, forty percent of individuals had nodules in the lung and 8 
smokers had bronchogenic carcinoma. Heavy smoking with pack years > 
40 has a definite risk of development of bronchogenic carcinoma, this 
being substantiated by our study.
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SYMPTOM ANALYSIS IN BRONCHOGENIC CARCINOMA
The  most  common  presenting  complaint  in  our  study  is  cough 
which was present in almost all patients. The next common symptom is 
dyspnoea which is present in 57 % of patients. Hemoptysis and chest pain 
were present in 51% and 44% of patients. Hiccough, hoarseness of voice, 
dysphagia, brachial neuralgia are seen in a small proportion of patients.
In  a  study  conducted  by  Jindal  and  Behera  19908,  the  most 
common  symptoms  are  cough  with  expectoration,  chest  pain  and 
hemoptysis, which coincides with our study. In India, where tuberculosis 
is rampant it is not uncommon to find a lung cancer patient being treated 
for tuberculosis initially. However, age of the patient, smoking history, 
mediastinal symptoms such as hoarseness of voice, SVC obstruction and 
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dysphagia favors the diagnosis of lung cancer.
In  our  study  we  couldn’t  find  any  correlation  between  the 
symptoms and location or pathological type of  bronchogenic carcinoma.
55
RELATIONSHIP OF CLUBBING WITH PATHOLOGICAL TYPE 
OF BRONCHOGENIC CARCINOMA
Out of 29 patients with squamous cell carcinoma 17 patients had 
clubbing. Among 11 patients with adenocarcinoma only 2 patients had 
clubbing.  The  correlation  between  clubbing  and  squamous  cell 
carcinoma is found to be statistically significant p value < 0.05 in our 
study. 
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In a study conducted by CM shetty et al in manipal3, clubbing was 
present more commonly in squamous cell carcinoma followed by adeno 
and small cell carcinoma. Eventhough clubbing has been associated with 
squamous  cell  carcinoma,  there  are  not  much  of  studies  to  correlate 
clubbing with various pathological types of bronchogenic carcinoma. Our 
study shows a definite correlation between clubbing and squamous cell 
carcinoma.
RELATIONSHIP BETWEEN SVC OBSTRUCTION AND 
PATHOLOGICAL TYPE OF BRONCHOGENIC CARCINOMA
Out of  45 patients only 2 patient had SVC obstruction and they 
both turned out to be squamous cell carcinoma. The most common cause 
of SVC obstruction is squamous cell carcinoma and small cell carcinoma. 
Since  our  study  population  is  less  we  couldn’t  derive  a  statistically 
relevant  correlation  between  SVC  obstruction  and  bronchogenic 
carcinoma.
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INCIDENCE OF PATHOLOGICAL TYPES OF BRONCHOGENIC 
CARCINOMA
The  most  common  type  of  bronchogenic  carcinoma  as  per  our 
study is  squamous cell  carcinoma which constitutes  64% of  the total. 
Adenocarcinoma ranks the second forming 27%, followed by small cell 
carcinoma cosnstituting 9 percent.
In a study conducted by Kashyap et al16 ,2001 done in northwestern 
region  of  india  sqaumous  cell  carcinoma  constitutes  58.3%,  adeno 
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carcinoma 10.8% and remaining formed by other cell types. In a study 
conducted in rajasthan by Gupta, squamous cell carcinoma is the most 
common pathological type. In a study conducted by Gupta et al15 2001 in 
Chandigarh, the most common malignancy is squamous cell carcinoma 
forming  60%  and  adenocarcinoma  forming   16.2  percent.  The  both 
studies correlates with our study.
RELATIONSHIP BETWEEN PATHOLOGICAL TYPE AND SEX 
OF THE PATIENT
In our study, among 29 patients with squamous cell carcinoma 27 
patients  were  males  and  2  were  females.  Out  of  12  patients  with 
adenocarcinoma, 2 patients were females and 10 patients were females. 
In a study conducted in pakistan in 20062, female sex is associated 
with  adenocarcinoma  and  male  sex  with  squamous  and  small  cell 
carcinoma.  A prospective study at Sweden found that adenocarcinoma 
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being the most  common type among female population and squamous 
cell carcinoma in males. In contrast to these studies no definite statistical 
correlation between adenocarcinoma and females could be made in our 
study. This could be explained by less number of females affected in our 
study.
CORRELATION BETWEEN PATHOLOGICAL TYPE AND 
LOCATION OF BRONCHOGENIC CARCINOMA
Out of 29 patients with squamous cell carcinoma, 20(69%) patients 
had central tumor and remaining 9(31%) had peripheral tumor. Among 12 
patients  with  adenocarcinoma  9(75%)  had  peripheral  and  3(25%)  had 
centrally placed tumor. The four patients with small cell carcinoma had 
their lesion located centrally. Chi square  was done and t score analysed. 
P value is <0.05 which is found to be statistically significant. 
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In an review article presented by D. Behera and T. Balamugesh7 in 
February 2004 from PGI Chandigarh who analysed the various studies in 
bronchogenic  carcinoma  in  india,  concluded  that  Adenocarcinoma 
presents as a peripheral mass in 61% of cases and in 38.3% as a central 
lesion.  Presentation as  a  central  mass  (72.2% cases)  is  more common 
among  squamous  cell  carcinoma  than  as  a  peripheral  lesion  (27.8%). 
Small  cell  cancer  also  presents  more  commonly  as  a  central  lesion 
(83.6%) than as a peripheral lesion (16.4%). This review coincides with 
our  study  and  adenocarcinoma  presenting  as  peripheral  lesion, 
squamous cell carcinoma presenting as central lesion was proved to 
be statistically significant.
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RELATIONSHIP BETWEEN THE RADIOLOGICAL PATTERN 
AND PATHOLOGICAL TYPE OF BRONCHOGENIC 
CARCINOMA
The most common radiological presentation in our study is mass 
lesion  with  or  without  collapse  of  lung.  Out  of  45  patients,  31 
patients(69%)  presented  as  mass  lesion  in  the  lung,  7  patients(15%) 
presented as pleural  effusion,  5 patients(11%) presented as obstructive 
pneumonia. 
Among  29  patients  with  squamous  cell  carcinoma  23  patients 
(79%)  presented  as  mass  lesion,  followed  by  pleural  effusion  and 
obstructive  pneumonia.  Among  12  patients  with  adeno  carcinoma  5 
patients(41%)  presented  as  mass  lesion,  3  patients(25%)  as  pleural 
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effusion and 3(25%) patients as obstructive pneumonia. In the small cell 
carcinoma  three  patients  presented  as  mass  lesion  and  one  patient  as 
obstructive pneumonia.
In an review article presented by D. Behera and T. Balamugesh in 
February 20047 from PGI Chandigarh, Mass with or without collapse is 
the  commonest  radiological  finding  in  lung  cancer  in  Indian  patients. 
Other  findings  include  pleural  effusion  in  25.1%,  rib  erosion  and 
lymphangitis.  Isolated  pleural  effusion  has  been  reported  in  3.8%  in 
squamous cell lung cancer, 22% in adenocarcinoma and only 4% in small 
cell lung cancer. These findings correlates with our study.
In  our  study,  mediastinal  invasion  is  present  in  2  patients  of 
adenocarcinoma, one patient of squamous cell carcinoma and small cell 
carcinoma.  Rib  erosion  was  noted  in  5  patients  with  squamous  cell 
carcinoma and 5 patients with adenocarcinoma. Cavitation was seen in 
one patient with squamous cell carcinoma.
In a study conducted in northern india in Chandigarh1, mediastinal 
invasion was present in 19% of patients, rib erosion was present in few 
patients. This correlates with our study.
INCIDENCE OF METSTASIS IN VARIOUS PATHOLOGICAL 
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TYPES OF BRONCHOGENIC CARCINOMA
In  our  study  most  common site  of  metastasis  is  supraclavicular 
lymph node followed by liver,  brain metastasis.  The other  uncommon 
sites  of  metastasis  were  skeletal,  adrenal   and  spleen.  Most  of  the 
metastasis were seen with squamous cell carcinoma.
In a study conducted in northern india Chandigarh1, the commonest 
site  of  metastasis  were  supraclavicular  lymph node(26%) followed  by 
liver(10%) and brain(4%). 
In a study conducted in korea4 the most common site of metastasis 
is  supraclavicular  lymphnode  followed  by  liver,  skeletal  and  brain 
metastasis. Both studies correlates with our study.
INCIDENCE OF BRONCHOGENIC CARCINOMA IN VARIOUS 
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LOBES OF LUNG
Right upper lobe constitutes 33% of brocnchogenic carcinoma, left 
upper lobe 27%, right lower lobe 27% followed by left lower lobe and 
right  middle  lobe.  Right  side  constitutes  66%  of  the  bronchogenic 
carcinoma. In our study the most common lobe involvement is upper lobe 
and the most common side involved is right side.
In a study conducted in korea4 right lung was involved in 60% of 
patients and left lung was involved in 40% of patients. Upper lobe was 
predominantly involved when compared to lower lobe involvement.
In  an  review  article  presented  by  D.  Behera  and  T.  Balamugesh  in 
February 20047 from PGI Chandigarh,  Upper zone is involved in most 
cases followed by mid zone (32.7%), lower zone (16%) and the entire 
lung (8.8%). These findings correlates with our study.
COMPARISON OF OUR STUDY WITH OTHER INDIAN LARGE 
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STUDIES
Various 
studies Total
Male: 
female Age
Smoker: 
non 
smoker
Squa
mous 
cell 
carcin
oma
Adeno 
carcin
oma
Anaplastic 
carc 
inoma
Kashyap 
et al 
200116
638 6.17 54.6 2.4 58.3 - 10.81
Gupta et 
al 200115 265 7.8
50 to 
70 3.6 60 21.5 16.2
Thippann
a et al 
1998 13
160 8.4 40 to 60 4 67.5 8.8 18.7
Rajaseka
ran et al 
199311
232 7.9 53 2.7 72 4.3 3.9
Jindal 
and 
Behera 
19908
1009 4.5 54.3 2.7 34.3 27.6 25.9
Our 
study 
2008
45 14 59 9.1 64.4 26.6 -
This table shows the comparison of various large studies in india 
with  the  present  study.  The  mean  age  of  incidence  of  bronchogenic 
carcinoma coincides with the other studies. As in other studies the most 
common type of bronchogenic carcinoma is squamous cell type followed 
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by adenocarcinoma and then other types. The incidence of bronchogenic 
carcinoma in females is much less in the present study when compared to 
other studies. Smoking: non smoking ratio is more in the present study 
when  compared  to  other  studies.  This  can  be  explained  by  the  less 
incidence of carcinoma in females in our study.
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CONCLUSION
In our study of 45 patients,
• The  incidence  of  bronchogenic  carcinoma  is  more  common  in 
males compared to females, partly attributed to the low incidence 
of smoking in south Indian people.
• Highest age incidence is seen in fifth decade of life which is early 
when  compared  to  other  studies  is  due  to  Increased  smoking, 
urbanisation, and the introduction of new industries.
• Cigarette  smoking  is  strongly  associated  with  bronchogenic 
carcinoma. Most of the females are non smokers.
• Bidi  smoking is  the commonest  pattern of  smoking habit  found 
which  is  associated  with  slightly  higher  risk  of  bronchogenic 
carcinoma when compared to cigarettes.
• All pathological types of bronchogenic carcinoma were associated 
with smoking.
• Heavy  smoking  with  pack  years  >  40  has  a  definite  risk  of 
development of bronchogenic carcinoma.
• Cough,  hemoptysis  and  breathlessness  were  the  common 
complaints in bronchogenic carcinoma.
• Clubbing has a definite correlation with squamous cell carcinoma.
• Adeno  carcinoma  is  associated  with  peripheral  lesion  while 
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squamous  and  small  cell  carcinoma  is  associated  with  central 
lesion.
• Squamous  cell  carcinoma is  the  most  frequent  histological  type 
followed by adenocarcinoma.
• The most common radiological pattern found is mass lesion with or 
without  collapse  followed  by  pleural  effusion  and  obstructive 
pneumonia.
• The most common site of metastasis is supraclavicular lymph node 
followed by liver, brain metastasis.
• The most common lobe involvement is upper lobe and the most 
common side involved is right side.
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PROFORMA
Serial No:                               Occupation: Asbestos exposure
Patients Name:                       Income:
IP No:                                 Educational Standard:
Age:
Address:                                                                  
History of presenting illness:
1) Cough                                    Duration:
2) Chest Pain                              Duration:
3) Hemoptysis
4) Mediastinal Syndrome
5) Superior Venacava Syndrome:
6) Horners Syndrome:
7) Hiccough
8) Hoarseness of voice:
9) Dysphagia
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Past History of Pulmonary Tuberculosis-
Smoking Habits:
              Type: Cigarette                 No:of Pack years
                        Beedi
                        Pipe smoking
                        Snuff
Tobacco chewing:
Family history of Bronchogenic Carcinoma
General Examination:
1) Build and Nourishment:
2) Clubbing:
3) Lymphadenopathy:
4) SVC Obstuction:
5) Paraneoplastic Manifestation:
6) Jaundice:
Vital Signs:
       Pulse                                           Temp
        RR                                              BP
Respiratory System:
1) Shape of Chest:
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2) Tracheal Position:
3) Movements:
4) Expansion:
5) Percussion:
6) Breath Sounds:
7) VF, VR
8) Added sounds:
9) Others
Examination of Abdomen:      Liver:
      Spleen:
      Free fluid
Examination of Nervous System:
1) Fundus
2) Horners Syndrome
3) Small muscle wasting in hands
Investigations:
1) Biochemical: Urea, Creatinine, Calcium level, Electrolytes
2) Xray Chest PA, Lateral View:
      Location of lesion:
                     Central
                     Peripheral
     Type of Lesion:
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                    Obstructive Pneumonia
                    Mass lesion
                    Pleural Effusion
                    Mediastinal Invasion
                    Rib Erosion:
                    Calcification
                    Cavitation
3) Sputum Cytology for Malignant cells
4) Bronchoscoy:
        Location
        BAL lavage
5) CT Scan Thorax
6) Histopathological Diagnosis:
     CT guided Biopsy
     Bronchoscopic Biopsy
     Others- Evidence of metastasis.
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